The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Naga Chalasani; Zobair Younossi; Joel E. Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A. Harrison; Elizabeth M. Brunt; Arun J. Sanyal

doi:10.1002/hep.29367

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Naga Chalasani, Zobair Younossi, Joel E. Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A. Harrison, Elizabeth M. Brunt, Arun J. Sanyal

Division of Anatomic and Molecular Pathology (AMP)

Research output: Contribution to journal › Article › peer-review

3224 Scopus citations

Original language	English
Pages (from-to)	328-357
Number of pages	30
Journal	Hepatology
Volume	67
Issue number	1
DOIs	https://doi.org/10.1002/hep.29367
State	Published - Jan 2018

Access to Document

10.1002/hep.29367

Cite this

@article{912e5b3ea4ce40f590df0a00c6f2f270,

title = "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases",

author = "Naga Chalasani and Zobair Younossi and Lavine, {Joel E.} and Michael Charlton and Kenneth Cusi and Mary Rinella and Harrison, {Stephen A.} and Brunt, {Elizabeth M.} and Sanyal, {Arun J.}",

note = "Funding Information: Abbreviations: AASLD, American Association for the Study of Liver Diseases; ACG, American College of Gastroenterology; AIH, autoimmune hepatitis; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; AUROC, area under the receiver operating curve; BMI, body mass index; CI, confidence interval; CLD, chronic liver disease; CT, computed tomography; CVD, cardiovascular disease; ELF, Enhanced Liver Fibrosis; FDA, U.S. Food and Drug Administration; FIB-4, fibrosis-4 index; FLD, fatty liver disease; GFR, glomerular filtration rate; GLP-1, glucagon-like peptide-1; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDL, high-density lipoprotein; HF, hepatic fibrosis; HS, hepatic steatosis; ICD-10, International Classification of Diseases, Tenth Revision; IR, insulin resistance; LDL, low-density lipoprotein; LT, liver transplantation; METs, metabolic equivalents; MetS, MetS, metabolic syndrome; MR, magnetic resonance; MRE, MR elastography; MRI, magnetic resonance imaging; NAFL, nonalcoholic fatty liver; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score; NASH, nonalcoholic fatty liver disease; NASH CRN, NASH Clinical Research Network; NFS, NAFLD fibrosis score; NIAAA, National Institute on Alcohol Abuse and Alcoholism; OCA, obeticholic acid; PNPLA-3, patatin-like phospholipase domain-containing protein 3; PPAR, peroxisome proliferator-activated receptor gamma; RCT, randomized controlled trial; SAF, Steatosis Activity Fibrosis; SH, steatohepatitis; T2DM, type 2 diabetes mellitus; TE, transient elas-tography; TG, triglyceride; TONIC, treatment of nonalcoholic fatty liver disease in children; UDCA, ursodeoxycholic acid; ULN, upper limit of normal; VCTE, vibration controlled transient elastography; WD, Wilson{\textquoteright}s disease.",

year = "2018",

month = jan,

doi = "10.1002/hep.29367",

language = "English",

volume = "67",

pages = "328--357",

journal = "Hepatology",

issn = "0270-9139",

number = "1",

}

TY - JOUR

T1 - The diagnosis and management of nonalcoholic fatty liver disease

T2 - Practice guidance from the American Association for the Study of Liver Diseases

AU - Chalasani, Naga

AU - Younossi, Zobair

AU - Lavine, Joel E.

AU - Charlton, Michael

AU - Cusi, Kenneth

AU - Rinella, Mary

AU - Harrison, Stephen A.

AU - Brunt, Elizabeth M.

AU - Sanyal, Arun J.

N1 - Funding Information: Abbreviations: AASLD, American Association for the Study of Liver Diseases; ACG, American College of Gastroenterology; AIH, autoimmune hepatitis; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; AUROC, area under the receiver operating curve; BMI, body mass index; CI, confidence interval; CLD, chronic liver disease; CT, computed tomography; CVD, cardiovascular disease; ELF, Enhanced Liver Fibrosis; FDA, U.S. Food and Drug Administration; FIB-4, fibrosis-4 index; FLD, fatty liver disease; GFR, glomerular filtration rate; GLP-1, glucagon-like peptide-1; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDL, high-density lipoprotein; HF, hepatic fibrosis; HS, hepatic steatosis; ICD-10, International Classification of Diseases, Tenth Revision; IR, insulin resistance; LDL, low-density lipoprotein; LT, liver transplantation; METs, metabolic equivalents; MetS, MetS, metabolic syndrome; MR, magnetic resonance; MRE, MR elastography; MRI, magnetic resonance imaging; NAFL, nonalcoholic fatty liver; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score; NASH, nonalcoholic fatty liver disease; NASH CRN, NASH Clinical Research Network; NFS, NAFLD fibrosis score; NIAAA, National Institute on Alcohol Abuse and Alcoholism; OCA, obeticholic acid; PNPLA-3, patatin-like phospholipase domain-containing protein 3; PPAR, peroxisome proliferator-activated receptor gamma; RCT, randomized controlled trial; SAF, Steatosis Activity Fibrosis; SH, steatohepatitis; T2DM, type 2 diabetes mellitus; TE, transient elas-tography; TG, triglyceride; TONIC, treatment of nonalcoholic fatty liver disease in children; UDCA, ursodeoxycholic acid; ULN, upper limit of normal; VCTE, vibration controlled transient elastography; WD, Wilson’s disease.

PY - 2018/1

Y1 - 2018/1

UR - http://www.scopus.com/inward/record.url?scp=85030176004&partnerID=8YFLogxK

U2 - 10.1002/hep.29367

DO - 10.1002/hep.29367

M3 - Article

C2 - 28714183

AN - SCOPUS:85030176004

VL - 67

SP - 328

EP - 357

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Access to Document

Other files and links

Cite this